key: cord-0613849-l81jzqcc authors: Wang, Shuang; Du, Jian title: A comment-driven evidence appraisal approach for decision-making when only uncertain evidence available date: 2021-12-05 journal: nan DOI: nan sha: abd90dbf9842a2447208a0f56d0332ebaa5aacc4 doc_id: 613849 cord_uid: l81jzqcc Purpose: To explore whether comments could be used as an assistant tool for heuristic decision-making, especially in cases where missing, incomplete, uncertain, or even incorrect evidence is acquired. Methods: Six COVID-19 drug candidates were selected from WHO clinical guidelines. Evidence-comment networks (ECNs) were completed of these six drug candidates based on evidence-comment pairs from all PubMed indexed COVID-19 publications with formal published comments. WHO guidelines were utilized to validate the feasibility of comment-derived evidence assertions as a fast decision supporting tool. Results: Out of 6 drug candidates, comment-derived evidence assertions of leading subgraphs of 5 drugs were consistent with WHO guidelines, and the overall comment sentiment of 6 drugs was aligned with WHO clinical guidelines. Additionally, comment topics were in accordance with the concerns of guidelines and evidence appraisal criteria. Furthermore, half of the critical comments emerged 4.5 months earlier than the date guidelines were published. Conclusions: Comment-derived evidence assertions have the potential as an evidence appraisal tool for heuristic decisions based on the accuracy, sensitivity, and efficiency of evidence-comment networks. In essence, comments reflect that academic communities do have a self-screening evaluation and self-purification (argumentation) mechanism, thus providing a tool for decision makers to filter evidence. Decisions are the acts that turn information into action or turn evidence into policy. The need to make effective and efficient health decisions is inescapable, regardless of whether the scientific evidence in place is robust or lacking 1 2 . How to make the best clinical decision from incomplete and uncertain evidence is a common issue, especially in COVID-19 global pandemic 3 . Uncertainty, including probability, ambiguity, and complexity, is always existing in healthcare decision-making scenarios 4 . A summary of data reported that nearly half (47%) of all treatments for clinical prevention or treatment were of unknown effectiveness and an additional 7% involved an uncertain tradeoff between benefits and harms 5 . In addition to the uncertainty about the effects of medical interventions, the timeliness of healthcare decisions needs to be further improved, especially in emergent scenarios. Healthcare decisions primarily rely on clinical practice guidelines and systematic reviews, which synthesize high-quality primary evidence. Nevertheless, as a highly complex process of translating best evidence to best practice, guideline development is time-consuming and requires about 2 to 3 years on average, which is insufficient to satisfy the needs in urgent situations 6 . In the current COVID-19 global pandemic, practitioners must make rapid therapeutic decisions from incomplete, uncertain, and even conflicting scientific evidence. Unproven drugs' use advocated by some physicians and politicians in the early period of COVID-19 may have contributed to the COVID-19 death rates 7 . This devastating global public health crisis reminded scientific researchers and policy makers of the significance of making effective decisions promptly for emergent events even when only limited evidence available. Most recently, the coevolution of science and policy in COVID-19 has been validated by linking scientific publications and policy documents for both global and China 8 9 . Nevertheless, they failed to reveal the detailed coevolution between scientific evidence and policy recommendations, for example, the selection mechanisms of the included evidence. Science is uncertain inherently. However, policy must be determined. Evidence appraisal, the critical evaluation of published studies, plays an important role in differentiating good science from bad science by uncovering problems in research. To take the first step to propel this complex coevolution, in this study, we proposed to use published research commentaries as a rapid evidence appraisal tool via providing clues to indicate the importance and validity of evidence for therapeutic decisions. Evidence appraisal is one of the three pivot tasks of a national system to deliver effective healthcare services, along with priority setting and clinical guidelines development 10 . One of the most valuable evidence appraisal approaches is published commentaries, which are expected to play an important role in evidence appraisal 11 . Published research commentaries are formal and short communications that reflect commenters' viewpoints by neutrally commenting on, supporting, or challenging research publications, such as letters to the editor and editorials [12] [13] [14] . Two inherent characteristics, diversity (comprehensiveness) and timeliness, made research commentaries crucial in shaping clinical knowledge and indicating details of evidence quality which is imperative in developing clinical guidelines. First, commentaries evaluate clinical evidence (articles) from diverse perspectives, including the strengths and weaknesses of methodology and clinical aspects. Also, research commentaries may publish original research and case reports that may be insufficient to produce an original research article but cannot be neglected as vital evidence to supplement the field literature 15 . Moreover, commentaries may express audiences' inspiration from original research, which would encourage future studies. These make comments provide a comprehensive and diverse evaluation for a given article or research topic. As an essential part of post-publication peer review, comments were expected to connect current evidence and form the evidence appraisal assertions and even conclusions. Second, comments were published on time and are much more efficient than the long-time process of developing clinical practice guidelines. For clinical research, the mean and median time from publication of an article to the publication of comment was 6 months and 4 months, respectively. Compared to the slow-developing cycle of clinical guidelines, it responds to clinical circumstances more efficiently and advances the updates of clinical guidelines. Letters to the editor surrounding the protocols and reported results of randomized controlled trials (RCT), as one type of scientific commentaries, has been analyzed in previous studies. Such type of comment plays post-publication criticism on shaping clinical knowledge 12 16 17 . However, few studies have comprehensively illustrated how exactly research commentaries engage in clinical evidence appraisal and impact the shaping of clinical evidence on a large data scale. That was why this study was initiated. We would like to explore how comments involve in evidence appraisal specifically and to that extent they shape the clinical evidence paths. Based on prior work, this study was designed to utilize published research commentaries as an evidence appraisal tool in selecting promising research and alerting unsolid studies timely in emergent situations. We used current treatment candidates of coronavirus disease 2019 (COVID-19) for a case study, which is a fantastic example of how comments appraise and shape clinical evidence, and inspire new insights and how it could contribute to the development of clinical guidelines. The present study explores whether comment could be used as a systematic and efficient evidence appraisal assisting tool for evidence-based therapeutic decision-making, especially in such cases that missing, incomplete, uncertain, or even incorrect evidence acquired. Evidence-Comment Networks (ECNs) were constructed for evidence-comment pairs from PubMed indexed COVID-19 publications and the corresponding formal published comments. We aim to identify: 3. To what extent are assertions shaped by critical comments faster than the final released recommendations in guidelines? A workflow diagram is shown in Figure. 1. The whole process of data collection, preprocessing, and networks completion was conducted by Python 3.8. After COVID-19 evidence-comment pairs dataset was extracted, it is significant to explore which concepts are highly commented. Here we use a text mining tool called PubTator Central, which identified and annotated concepts from the title/abstract sentences of publications as either CellLine, Chemical, DNAMutation, Disease, Gene, Genus, ProteinMutation, SNP, or Species. Concept identifiers come from multiple resources, such as MeSH and gene2pubmed 18 . All concepts with the same MeSH ID were standardized as corresponding MeSH descriptors. In general, the most common concepts are COVID-19 associated diseases, species, genes (infection mechanism), and drugs. What caught our attention was that three widely discussed drugs during COVID-19 chemicals-hydroxychloroquine, tocilizumab, and remdesivir-were detected from top 5 chemicals-related concepts by PubTator Central. Intuitively, the core section of clinical evidence come from evidence of the clinical treatment process (i.e., drug trials). In addition, as discussed above the unproven drugs usage contributing to COVID-19 deaths and the continuous controversy of the effect of candidate drugs, it would be a great case practice to use drugs as research objects for comment-driven evidence analysis. As drug has been determined as the research object, we dug deeper for more drug candidates. The top 15 chemicals-related concepts include 9 drugs which were hydroxychloroquine, tocilizumab (IL-6 receptor blockers), remdesivir, vitamin d, azithromycin, chloroquine, lopinavir/ritonavir, steroids, aspirin. To investigate the roles comments played in evidence appraisal, we referred to five versions of "Therapeutics and COVID-19: living guideline" by World Health Organization (WHO) and found 5 groups of matched drugs (hydroxychloroquine, IL-6 receptor blockers, remdesivir, lopinavir/ritonavir, and corticosteroid). As Ivermectin was involved in the WHO's series of guidelines, we then added it into research objects list. Finally, six groups of drugs (corticosteroid, remdesivir, hydroxychloroquine, lopinavir/ritonavir, ivermectin, and IL-6 receptor blockers) were chosen as research objects. The present work focused on evidence-comment publications of 6 therapeutic drugs for COVID-19 derived from PubMed. First, 17 records were excluded due to 12 PMIDs not being found, resulting in 9296 evidence-comment pairs in total, with 5320 records being commented (4200 primary research publications), and 8483 commentary publications. Next, to focus on six drugs, we extracted evidence-comment data whose titles include any of the six drug names. Two reviewers (SW and QYG) read all full texts of articles and comments to classify and annotate the topics of interest and the sentimental orientations for each comment. A third reviewer (JD) arbitrated when there was any conflict. The first is comment topics categorization. To explore the exact commentary points in evidence appraisal, comment topics were categorized based on Kastner et al.'s categorization frame of "Letter to the Editor" 16 . For each comment, one would go through the comment, locate the direct comment sentences, analyze the comment topic categories, and assign the comment to the groups it belongs to. In general, each comment was classified into two comment topic groups hierarchically. The first level categorizations are methodology, clinical themes, and other. Then under each group, comment topics would be further sub-classified, for example, clinical themesclinical practice related. Second, once we get to know what those comments were talking about (comment topics), it is of great benefit to figure out the overall comment sentiments, supportive, critical, or neutral. After going through the comments' full texts in the above section, two reviewers would locate the sentences with clear sentiment and label the overall sentimental orientation. After labeling of all full texts, 21 comments were excluded since some comments were in Spanish and could not be translated accurately or evidence-comment wrongly matched in PubMed. Finally, 168 evidence articles (146 primary research articles; 22 other research articles) and 376 accompanying comments left in this study, made up 427 evidence-comment pairs (354 evidencecomment pairs; 73 comment-comment pairs; 36 repeated records). Evidence-comment pairs had two groups in fact. One group was the real evidence-comment group, representing evidence articles being commented; the other group was the comment-comment group, meaning comments then being commented afterwards. In the followings, we used evidence-comment to represent the all the pairs. Fig. 2 showed the data collection and preprocessing process. The Cytoscape 3.9.0 software was utilized to draw ECNs. We finally included 168 publications relevant to six drugs (146 primary research articles), containing 376 comments, dated from 2003 May to 2021 July, resulting in 427 evidence-comment pairs. The descriptive analysis of 6 drugs were shown in table 1. A series of general characteristics of evidence and comments is summarized, containing evidence timespan, comment timespan, evidence count, comment count, evidence-comment pairs count, the count of subgraphs of each drug, and the count of nodes of the biggest subgraph of each drug. was not about remdesivir itself. It showed a network discussing 1) the effectiveness of remdesivir and 2) the combination effectiveness of lopinavir + ritonavir on COVID-19. Interestingly, the bridging node that connected these two studies is a review-type comment about immunodeficiency. In this comment, Hammarström 31 32 . Based on the leading two subgraphs of remdesivir, more critical comments received than supportive ones undermined the effectiveness of remdesivir, though uncertainties remained. The third version of WHO guidelines on 17 Dec 2020 firstly recommended against using remdesivir and lopinavir on COVID-19, disregarding the severity of diseases. The concrete recommendation here echoed the result of comment-driven evidence assertion 33 . We extracted the top two subgraphs of Lopinavir/Ritonavir (LPV/r) combination to analyze its treatment effect as Negative comments judged a series of methodology errors, such as the "sample size is so small", "crushing LPV/r tablets may weaken effect", "primary endpoint (speed to symptom resolution) may not be the best", and "late therapy and population selection bias" [34] [35] [36] [37] . In addition, it is worthy to note that besides pointing out the weakness of this trial, critical comments emphasized that not shutting the door on LPV/r RCT so early since "no benefits observed" does not mean inefficacy and "absence of evidence is not evidence of absence", declaring incremental clinical improvements were crucial even without statistical significance at this urgent time [36] [37] [38] . Such calls reflected folks' expectation for any possibility of hope and corresponded to the resume of the WHO SOLIDARITY trial later 39 . In sum, the comment-driven Authors' Reply statement from the first subgraph of LPV/r challenged the "no benefits finding" and considered this combination as a promising option though negative evidence was published. Since only one article was included in this LPV/r research-comment community, we went more profound to the second subgraph on the right for more information. However, evidence to the contrary was found. Lim, et al. 40 Lopinavir and darunavir are both HIV protease inhibitors and have similar structures. As a result, the second subgraph showed that the treatment of LPV/r was uncertain or even suspicious. To sum up, comments of the top 2 biggest subgraphs of LPV/r exhibited contrast attitudes. Given that the first subgraph on the left had more comments than the 2 nd subgraph, the integrated comment-driven assertion was that LPV/r was promising though negative evidence existed. Nevertheless, WHO guideline recommended against using HCQ and LPV/r on COVID-19, disregarding the severity of disease 33 . Considering these two graphs cannot represent the overall information of the LPV/r evidence-comment community, new evidence clues may reverse the assertion as keeping digging. This turned out the uncertainty of science exploration. Whereas, as we were exploring deeper, we were getting closer. A relevant absolute conclusion was not reached from the above evidence-comment networks. However, a more conclusive claim could be developed as more evidence-comment pairs joined together with consistent sentiments. In Fig. 7 47 54 . In this way, comment completed evidence appraisal by criticizing problematic evidence and providing related evidence to strengthen own position and thus connected relevant evidence forming ECNs. In the end, an HCQ + A treatment knowledge path was achieved from "efficacy found" to "efficacy negated" due to comments with challenging viewpoints. The third version of WHO guideline on 17 Dec 2020, firstly recommended against using HCQ on COVID-19, disregarding the severity of disease 33 . This was published posterior to the WHO SOLIDARITY trial on 15 Oct 2020, revealing the inefficacy of HCQ 39 . Rather, the WHO guideline was supported by a "living systematic review and network meta-analysis", which concluded HCQ + A do not seem to be beneficial in treating COVID-19 based on 5 clinical trials, 507 participants, including this intervention, with beneficial treatment evidence level as very uncertainty 55 . It was consistent with the results of our HCQ + A treatment evidence-comment network. In the network, the newest article on June 2020 indicated the uncertain effects of both HCQ solely and HCQ + A. Even though the WHO guideline did not directly refer to the papers (often the most original and preliminary evidence) in our network, this, in turn, proved the hypothesis that ECNs could be used as indirect evidence and early signs of the effect to clue the development of clinical guidelines. As a treatment candidate of COVID-19, corticosteroid, has been suggested the potent antiinflammatory effects to mitigate the deleterious effects, such as lung injury and multisystem organ dysfunction, caused by the systemic inflammatory response of severe COVID-19 56 . In contrast to direct antiviral effect, evidence of corticosteroid more focused on its safety and peripheral effects than virus-related efficacy. Therefore, we analyzed the top two sub-graphs of corticosteroid, as the biggest sub-graph only contains three nodes discussing the efficacy of corticosteroid. Fig. 8 exhibited these two subgraphs of corticosteroid. Authors' Reply of COVID-19 and suggested that "low-dose of corticosteroid therapy may not delay viral clearance", as fast viral clearance is an essential factor of recovery 58 . This suggested corticosteroid as a potential candidate for treating cytokine storm syndrome of patients with severe COVID-19, without the concern of the delay of viral clearance. However, this commentary received two conflicting comments afterwards. Boglione et al. The positive effect of corticosteroid on COVID-19 was revealed from the 2 nd biggest sub-graph. It began with an article about the antenatal administration of COVID-19 patients, mentioning that against the antenatal corticosteroid therapy for fetal lung maturity during pregnancy of patients with COVID-19, considering deleterious effects corticosteroid on COVID-19 61 . This article received five comments, and two of them discussed the usage of corticosteroid, including an authors' reply. Liauw et al. firstly refuted the conclusions of maternal harm since the impact of corticosteroid in nonpregnant was unclear; secondly, they argued that the absolute benefits of antenatal corticosteroid vary per week since the baseline risks of neonatal morbidity decreased as gestational age increased 62 . Then, interestingly, the authors replied and modified their original view with the new evidence of the efficacy of corticosteroid, recommended to use corticosteroid during pregnancy with the preterm risk to improve the neonatal outcomes 63 64 . The reversion made the 2 nd sub-graph determined the benefits of corticosteroid on COVID-19. Here, as this comment provided new evidence to the original research evidence which reversed the initial assertion, comment-derived evidence created. Based on the top 2 sub-graphs, the potential of corticosteroid on COVID-19 was detected, challenged, and further confirmed, and this may further evolve as new studies emerge. In addition, this finding corresponded to the first version of WHO guideline, which recommended to use corticosteroid on severe patients and conditionally recommended against using corticosteroid for non-severe patients. Corticosteroid was usually used to fight cytokine release syndrome (CRS), which would develop into severe or critically ill COVID-19 patients. There are seven sub-graphs related to ivermectin. After removing comment nodes not found or in Spanish, the top 2 biggest sub-graphs out of 7 were analyzed in detail, as shown in Fig. 9 . Since the nodes' number of the first biggest sub-graph is so small and no clear conclusion could be detected, we displayed the 2 nd sub-graph for supplementing the effectiveness analysis of ivermectin. As a result, the comment-driven conclusion from the two ECNs was that "ivermectin effective" was untenable. ivermectin being incorrectly interpreted as a treatment drug, thus causing a warning from FDA that "ivermectin in veterinary products should not be used for human therapy" 66 . In sum, the effectiveness of ivermectin cannot be concluded from the ECN on the left. Moreover, the FDA warning emphasized that it was misleading to consider ivermectin as an effective human treatment. The second biggest sub-graph on the right displayed a comment-driven "ivermectin effective: unsolid" assertion. Rajter et al. concluded that ivermectin was associated with lower mortality, 71 . This article received three critical comments, pointing out a series of methodology errors of the research, including chronology bias, low dosage intervention, not reporting two essential variables that may impact the results (time of symptom onset, patients' health insurance coverage) [72] [73] [74] . With all comments negative, the comment-driven conclusion from the network was that the efficacy of ivermectin was untenable. Based on the top 2 sub-graphs of ivermectin above, the comment-driven conclusion was that ivermectin was not practical for COVID-19. Correspondingly, WHO finally suggested not to use ivermectin for COVID-19 except for clinical trials in the 4 th version guideline 19 . This was a super exciting finding. Even though considerable peers were positive, a warning sign could be detected from comments to calm readers down, and this sign could trigger doubt about its validity. After combining to more sub-graphs, a reversed knowledge path of ivermectin would expectedly be detected. The first biggest sub-graph out of 36 sub-graphs about IL-6 receptor blockers was deeply explored, exhibiting that TCZ (IL-6 receptor blockers) was effective on severe COVID-19 patients in Fig. 10 . This was consistent with the latest version of the WHO guideline, which highly recommended using IL-6 receptor blockers in severe patients 19 . late stages to reinforce the statement that TCZ was effective [76] [77] [78] . This back and forth discussion made the comment and the author's reply as bridging comments connecting two relevant original studies and formed an evidence-comment network for the effectiveness of TCZ. 19 84 . This suggested that comments did evidence appraisal to promote the certainty of knowledge by clarifying (resolving) uncertainty as well as alerting (detecting) uncertainty. Specific illustrations are provided in Fig. 11 . When calculating the overall sentiments of each drug, the results were super interesting. Without considering specific topics articles were talking about (i.e., treatment efficacy, inefficacy, or mechanisms of action) and only computing the distribution of comment sentiments for each drug, the results were aligned with recommendations in WHO guidelines. In specific, WHO guidelines recommended using IL-6 receptor blockers (tocilizumab/sarilumab) and corticosteroid for patients with severe COVID-19. Only IL-6 receptor blockers (48; 25) and corticosteroid (28; 12) received more supportive comments than critical comments, as is shown in The consistency between comment sentiment and recommendation polarity (for vs against) has been validated above. To probe the sensitivity of comment, we compared the comment topics with the concerns of WHO guidelines and other evidence appraisal systems. We try to uncover whether comment topics were in accord with the core concerns of evidence appraisal criteria in the development of clinical practice guidelines and even beyond. The quality of evidence, especially the research methodology, is the most crucial determinator in developing guidelines and suggesting recommendations. Nevertheless, having a high quality of evidence does not signify a strong recommendation. Other factors affecting recommendations include clinical applications (significantly the benefit and risk of an intervention), patient values and preference, costs, etc. 92 93 The distribution of comment topics was plotted in the Fig. 13 . The overall distribution showed that the leading comment topic was methodology (54.42%), then followed by clinical themes (31.92%) and other (13.65%). These results aligned with Kastner et al.'s findings 16 . Under each category, the top three sub-categories of methodology topics were analysis (14.04%), intervention (10.38%), and study design (8.46%); in clinical themes topics, these were clinical practice related (11.54%), biological mechanisms (5.00%), and clinical evidence related (3.65%); in other topics, these were just mentioned (8.08%), ethical issues (2.12%), and evidence-based medicine (0.96%). Next, to further explore the topics distribution for each drug, we then plotted the sunburst chart of each candidate, respectively, as Fig. 14 below. Interestingly, different from the overall topics' distribution, IL-6 receptor blockers (57.29%, 28.13%) have more comments on clinical themes than methodology. For IL-6 receptor blockers, under clinical themes, the top 1 second-level topic is clinical practice related; this means that many comments talked about the issues of IL-6 receptor blockers in clinical practice. This makes sense since IL-6 receptor blockers were recently detected to be effective for severe patients recently, which corresponds to more clinical experience. In addition, comments could contribute to various aspects of decision-making beyond science, such as politics, economics, availability, and feasibility. In "other" category of our comment topics, Corticosteroid HCQ Ivermectin Remdesivir LPV/r especially in the subcategory of "Just mentioned", where commentors mentioned the research evidence without detailed appraisal but discussing something else related. For example, Self et al. demonstrated that HCQ was ineffective based on their RCT, and Saag commented on this article not to appraise evidence quality but to criticize that the infusion of politics into science resulted in the research craze of HCQ yet no benefits detected 94 . Decision-making is a complex process. Based on different action subjects, different associated factors would be taken into consideration. Comment has the potential to contribute on multiple sides of the process beyond science and beyond evidence quality appraisal. Finally, after analyzing the accuracy and sensitivity of comment-driven evidence appraisal, the most significant part is identifying its timeliness. The comment timespan of each drug was Dr. Horton firstly pointed out that, "Failure to recognize the critical footprint of primary research weakens the validity of guidelines and distorts clinical knowledge" 12 . He stressed the outstanding contribution of research commentaries to shape clinical knowledge, especially criticism, which enlightened our study 12 . After that, Dr. Weng argued the significant role comment played in evidence appraisal 11 . Our study systematically and quantitatively proved their assertions. Comment has the potential as a rapid evidence appraisal tool via providing clues to indicate the importance and validity of evidence for therapeutic evidence-based decision-making, especially in urgent scenarios. The present study revealed the crucial power of comment-driven evidence assertions by answering three questions, 1) how accurate 2) how sensitive (comprehensive) 3) how fast. Once these three conditions were met, the power of evidence-comment network as an evidence appraisal tool in detecting promising evidence and alerting potential risks in emergent situations was preliminary proved. Regarding the six groups of drug candidates, except LPV/r, the detected effectiveness from the top subgraphs of the rest 5 drugs were consistent with WHO guidelines. Remdesivir, HCQ, and ivermectin were respectively found uncertain or denied efficacy on COVID-19 based on the drug effect relevant evidence-comment paths in their top subgraphs. WHO guidelines recommended against using these drugs as well. For corticosteroid and IL-6 receptor blockers, the top subgraphs revealed the efficacy on severe COVID-19, especially its effect on CSR, and WHO guidelines also recommended using them. Only for LPV/r, comments of the first biggest subgraph considered it a promising candidate, though the second small subgraph of LPV/r thought the effectiveness was uncertain. For evidence validation, guidelines were recommended against using it. As more subgraphs of LPV/ being explored, more information, including reversed evidence, may be disclosed. However, as for the biggest ECNs analysis for each drug, by validating clinical guidelines, the knowledge accuracy of ECNs was 5/6. In terms of incomplete information of the top biggest subgraphs, the present study further analyzed the overall comment sentiment for each drug. Surprisingly, the overall sentimental orientation fully aligned with the recommendation propensity of WHO guidelines. That is, corticosteroid and IL-6 respectively, have more supportive comments than critical comments, and finally, guidelines recommended using them on severe COVID-19 patients. Remdesivir, HCQ, ivermectin, and LPV/r respectively have more critical comments than supportive comments, and correspondingly guidelines recommended against using them. Even though, based on the LPV/r effect relevant research and comments from its top subgraphs, this combination was considered the potential treatment. The accuracy of comment-driven evidence was proved initially from the above analysis. Inspired by these findings, we proposed that comment sentiment analysis could be used as a simple, straightforward tool of heuristic decision making, which means making decisions with limited information in urgent situations. In the case of drug effects based on ECNs, locating evidencecomment pairs related to a specific drug, without considering whether the scientific evidence was directly about the effectiveness or not, whether the effectiveness was positive or negative, or whether the comment was directly relevant to the topic or not, just rely on the overall comment sentiment towards the drug and one can conclude. This would be super helpful when only knowledge of uncertainty existed for decision-making. It was a boldly preliminary proposal regarding ECN as an evidence appraisal tool, a more detailed design of the tool would be elaborated below. Compared to the overall evidence accuracy in decision-making, the sensitivity of comment is significant at the same time, which guarantees the sustainability and promotability of accurate Moreover, besides the variety of comment topics, the points that commentaries focused on were in accord with the concerns of current grade systems (i.e., GRADE). As an overall clinical evidence appraisal system, GRADE evaluated evidence quality firstly based on study design, RCT/observational research 93 . Study design (i.e., RCT or not), as the 4th common comment topic in our study, was consistent with the concerns' priority of GRADE. In addition, effectiveness, as GRADE's first level up evidence, is the 2 nd common topic in our analysis. All these matched points further proved the consistency between comment topics and concerns of grading guidelines. Accuracy and sensitivity are the prerequisites to enable comment-driven evidence appraisal to aid clinical policymaking. However, what makes it the most competitive is the timeliness. First, evidence being commented on means the significance or controversy of the research article. Screening research evidence via "has comment" linkage in PubMed has already filtered out those side articles and induced the appraisal scope. Second, the present study found that the first critical comment was detected 8 months on average before the guideline release. Besides, on average 4.25 months earlier than guidelines, half of the critical comments had already accumulated, which indicated the critical comments is an early sign for the recommendation in guideline. The biggest issue for clinical guidelines is the slow-developing process. If an approach from the perspective of informatics could help fast detect critical signs or assertions, it would provide hinds for clinical guidelines development. Furthermore, the timeliness made the comment-driven method powerful for evidence appraisal when fast decisions are needed in urgent situations. Scientific commentaries are an important way of formal academic community, but these data remain underutilized. Based on the above analysis of evidence-comment networks, commentdriven evidence assertions were able to do evidence appraisal in an accurate, precise, and fast way. How to take advantage of this tool in a simple but powerful way becomes a worthy discussing For a given article, each comment was analyzed to identify its comment topics and comment sentiment. All comment topics would then be matched to the scale's comment categories. Once matched to a topic of the scale, the average score of all comments under each topic was the topic score. This avoided the problem of incomprehensive comment topics. In other words, an article received many comments, but they all concentrated on one topic. The final overall score is the sum of each topic score. Therefore, to take advantage of this tool efficiently, we suggested that medical journals label comment sentiment and topics once accepted comments for publishing. This could help create structured data for calculating comment-driven evidence assertions. Dr. Chunhua Weng has expressed a similar view on the Lancet by using controlled vocabulary, such as "lacks equipoise", to re-present journal articles (comments) 11 . This could be used to build a knowledge base to connect clinical research and their comments in a structured format to leverage the potential of scientific commentaries in evidence appraisal. Despite multiple remarkable new findings, this article has some limitations as well. Firstly, this study only considers PubMed publications. In addition, whether comments are made without any conflicting interests is not considered. If such a comment on behalf of a particular stakeholder exists, its effectiveness in evidence appraisal should be weak because it loses objectivity. For the next step, based on this current study, we will extract all randomized clinical trials (RCTs) and their comments from PubMed for evidence-comment network analysis. A dynamic clinical knowledge platform built from evidence-comment networks will be established with the analysis results. This could serve as a clinical knowledge base from which healthcare providers and researchers can efficiently consolidate and expand field knowledge through given clinical ECNs based knowledge paths. Furthermore, this platform could serve as a crucial alert and supplement for developing clinical practice guidelines. This study intended to explore whether and how research commentaries could be used as an evidence appraisal tool cluing evidence-based decision making, especially fast decisions. We Specifically, the study conducted evidence-comment network analysis, sentiment analysis, comment topics analysis, and efficiency analysis. First, for ECNs analysis, out of 6 drug candidates, comment-driven evidence assertions of leading subgraphs of 5 drugs were consistent with WHO clinical therapeutics guidelines recommendations. The sentiment analysis further revealed that the overall comment sentiment of 6 drugs respectively corresponds with WHO clinical guidelines. This proved the accuracy of comment-driven evidence. Second, comment topics covered all significant points of evidence appraisal, from methodology, clinical themes, to other topics (i.e., ethical issues). What is more, the core topics that comment concentrated on, such as study design, were matched up with the concerns of guidelines and other evidence appraisals and even went further to politics, economics, etc. These findings revealed the comprehensiveness and precision of comment topics. Finally, the first half of critical comments emerged 4.25 months earlier on average than the release date of WHO guidelines, which made comment-driven assertions a timecompetitive appraisal tool. Based on the accuracy, sensitivity, and efficiency performance, comment has the potential as a rapid evidence appraisal tool via providing clues to indicate the importance and validity of evidence for therapeutic decisions. Comment has a selection effect by appraising the benefits, limitations, and other clinical practice issues of concern for existing evidence. Although negative comments are critical, they tend to provide a more detailed understanding of the results by introducing new views or evidence, and further shaped the knowledge assertions, rather than simply denying the key findings contained in the initial evidence. Comments also have the potential to inform decision-makers from various perspectives beyond science, such as economics, politics, and ethical issues, which are crucial aspects in policy making. Communicating Uncertainties About the Effects of Medical Interventions Using Different Display Formats Communicating scientific uncertainty Communicating Scientific Uncertainty in an Age of COVID-19: An Investigation into the Use of Preprints by Digital Media Outlets Medical decision making : an international journal of the Society for Understanding behavioral intent to participate in shared decision-making in medically uncertain situations Clinical practice guideline development manual: a qualitydriven approach for translating evidence into action Why do COVID death rates seem to be falling? Coevolution of COVID-19 research and China's policies. Health research policy and systems Coevolution of policy and science during the pandemic Knowing What Works in Health Care: A Roadmap for the Nation Post-publication peer review and evidence appraisals in primary care Postpublication Criticism and the Shaping of Clinical Knowledge Letter to the Editor When postpublication peer review stings Writing a letter to the editor What do letters to the editor publish about randomized controlled trials? A cross-sectional study Understanding the nature and scope of clinical research commentaries in PubMed PubTator Central: Automated Concept Annotation for Biomedical Full Text Articles WHO. Therapeutics and COVID-19: Living Guideline. In: Organization WH Exploring network structure, dynamics, and function using NetworkX Development of passive immunity against SARS-CoV-2 for management of immunodeficient patients-a perspective Compassionate Use of Remdesivir for Patients with Severe Covid-19 A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19 Coronavirus drugs trials must get bigger and more collaborative Compassionate Use of Remdesivir in Covid-19 Compassionate Use of Remdesivir in Covid-19 Remdesivir in covid-19 Compassionate Use of Remdesivir in Covid-19 Compassionate Use of Remdesivir in Covid-19 Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial The Adaptive COVID-19 Treatment Trial-1 (ACTT-1) in a real-world population: a comparative observational study COVID-19 Therapeutics: Making Sense of It All WHO. Therapeutics and COVID-19: Living Guideline. In: Organization WH A Trial of Lopinavir-Ritonavir in Covid-19 Crushing lopinavir-ritonavir tablets may decrease the efficacy of therapy in COVID-19 patients A Trial of Lopinavir-Ritonavir in Covid-19 A Trial of Lopinavir-Ritonavir in Covid-19 A Trial of Lopinavir-Ritonavir in Covid-19 Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT-PCR Letter to the Editor: Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR Darunavir does not prevent SARS-CoV-2 infection in HIV patients Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France Early Outpatient Treatment of Symptomatic, High-Risk COVID-19 Patients That Should Be Ramped Up Immediately as Key to the Pandemic Crisis Dangers of the use of hydroxychloroquine and azithromycin combination in COVID-19 patients Does Combining Severe and Mild Cases of COVID-19 Produce Low Fatality Rates After Treatment With Hydroxychloroquine and Azithromycin? Apparent inefficacy of hydroxychloroquine combined with azithromycin on SARS-CoV-2 clearance in an incident cohort of geriatric patients with COVID-19 EARLY OUTPATIENT TREATMENT OF SYMPTOMATIC, HIGH-RISK COVID-19 PATIENTS THAT SHOULD BE RAMPED UP IMMEDIATELY AS KEY TO THE PANDEMIC CRISIS How to Consider Low Reported Death Rates in COVID-19 Impact of Hydroxychloroquine on Antibody Responses to the SARS-CoV-2 Coronavirus Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State Drug treatments for covid-19: living systematic review and network meta-analysis Clinical progression of patients with COVID-19 in Shanghai Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19 The proper use of corticosteroids for 2019-nCov pneumonia: Towards promising results? Re: Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19 COVID-19) and pregnancy: what obstetricians need to know Antenatal corticosteroids and COVID-19: balancing benefits and harms Dexamethasone in Hospitalized Patients with Covid-19 The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro Ivermectin and COVID-19: A report in Antiviral Research, widespread interest, an FDA warning Ivermectin and COVID-19: Keeping Rigor in Times of Urgency Continuous high-dose ivermectin appears to be safe in patients with acute myelogenous leukemia and could inform clinical repurposing for COVID-19 infection Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19 Ivermectin for COVID-19: Promising but not yet conclusive Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The Ivermectin in COVID Nineteen Study Standard Dose Ivermectin for COVID-19 Chronologic Bias, Confounding by Indication, and COVID-19 Care Remarks About Retrospective Analysis of Ivermectin Effectiveness on Coronavirus Disease 2019 (ICON Study) Effective treatment of severe COVID-19 patients with tocilizumab Safety concerns regarding concomitant use of tocilizumab and glucocorticoids in COVID-19 patients Tocilizumab treatment in COVID-19: A single center experience Tocilizumab treatment in COVID-19 patients needs the assessment of the disease severity and timely intervention COVID-19 pneumonia treated with Sarilumab: A clinical series of eight patients Anti-IL6R role in treatment of COVID-19-related ARDS Favorable changes of CT findings in a patient with COVID-19 pneumonia after treatment with tocilizumab Off-label use of tocilizumab in patients with SARS-CoV-2 infection Why tocilizumab could be an effective treatment for severe COVID-19? Utilizing tocilizumab for the treatment of cytokine release syndrome in COVID-19 Are there any association between COVID-19 severity and immunosuppressive therapy? Use of subcutaneous tocilizumab in patients with COVID-19 pneumonia Does tocilizumab have a magical therapeutic effect on COVID-19 patients without obvious adverse reactions? Tocilizumab treatment should be used in a timely manner, at suitable dose, and in suitable patients Acute hypertriglyceridemia in patients with COVID-19 receiving tocilizumab Does use of propofol aggravate the inflammatory markers and cause propofol infusion syndrome in intubated cases of severe COVID-19 infections Effect of Best Practice Advisories on Sedation Protocol Compliance and Drug-Related Hazardous Condition Mitigation Among Critical Care Patients GRADEing quality of evidence and its importance in evidence-based practice Understanding GRADE: an introduction Misguided Use of Hydroxychloroquine for COVID-19: The Infusion of Politics Into Science Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group